Alpha Tau Medical Ltd ((DRTS)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alpha Tau Medical Ltd (DRTS) is conducting a clinical study titled ‘A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer.’ The study aims to evaluate the safety and efficacy of Alpha DaRT combined with chemotherapy in treating pancreatic cancer. The primary focus is on safety, assessing adverse events, while secondary objectives include evaluating efficacy through survival rates and pain control.
The intervention being tested is the Diffusing Alpha Radiation Emitters Therapy (DaRT), a device designed to deliver targeted radiation therapy directly into tumors. This approach aims to enhance the effectiveness of chemotherapy in treating pancreatic cancer.
The study is interventional, non-randomized, and follows a parallel assignment model with no masking. It involves 30 participants divided into two cohorts, focusing on treatment as the primary purpose.
The study began on November 18, 2024, with an estimated primary completion date yet to be announced. The latest update was submitted on August 13, 2025, indicating ongoing recruitment.
This study update could influence Alpha Tau Medical’s stock performance positively, as successful outcomes may enhance investor confidence. The innovative approach may set the company apart in the competitive oncology treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.